Trajan Group Holdings Ltd · ASX:TRJ
Trajan — FY2024 Earnings Presentation
13 slides from Trajan's earnings presentation, Aug 29, 2024
Slide 1: Full Year FY24 Financial Results
Science that benefits people Enriching personal health through scientific tools and solutions 29 AUGUST 2024 Full Year FY24 Financial Results Stephen Tomisich Founder, CEO & Managing Director Alister Hodges CFO
Slide 2: Challenges to Opportunities: A Year in Review
Challenges to Opportunities: A Year in Review • Extraordinary industry wide issues impacting TRJ’s FY24 • Fundamentals of TRJ remain strong and supported our result: ability to navigate these factors and achieve Net Revenue within 5% of the previous year. • H1 – Destocking in the Components & Consum
Slide 3: Financial Summary
Financial Summary Net Revenue nEBITDA Core1 $155.0M FY23: $162.2M H1 FY24 $17.2M FY23:$23.9M 80.1 82.1 12.7 76.4 78.6 11.1 H1 FY23 10.3H1 FY23 63.9 H1 FY24 H1 FY24 7.7 43.7 6.9 5.5 June 2023 December 2024 Revenue nEBITDA - Core Cash Proforma Operating Balance Gross Margin NPATA2 $11.2M 41.1% $0.6M 3
Slide 4: Segment Reporting – Components & Consumables (Core)
Segment Reporting – Components & Consumables (Core) Components & Consumables: Net Revenue: Proforma nEBITDA of Includes parts, supplies, components, and consumable $96.2M Gross Profit $32.3M products across the Group. (FY23:$99.3M) Margin 41.1% (FY23:$33.8M) (FY23:44.7%) • Industry wide destocking a
Slide 5: Segment Reporting – Capital Equipment (Core)
Segment Reporting – Capital Equipment (Core) Proforma nEBITDA of Capital Equipment:Includes robotic workflow automation Net Revenue: systems, online and laboratory instruments, and parts and $53.9M Gross Profit $9.7M services related to them. (FY23:$57.3M) Margin 40.2% (FY23:$12.0M) (FY23:40.3%) • S
Slide 6: Segment Reporting – Disruptive Technologies
Segment Reporting – Disruptive Technologies Disruptive Technologies: includes products and Net Revenue: Proforma nEBITDA of services related to micro-sampling, (devices, services, $4.9M Gross Profit ($4.9M) and other related investments) as well as miniaturised, (FY23:$5.6M) Margin 52.7% (FY23:($4.4
Slide 7: Balance Sheet
Balance Sheet June 2023 June 2024 ($M) ($’M) • Non-current assets movement predominantly due to impairment expenses of $26.7M and FX revaluation on goodwill. Cash 11.0 11.2 Receivables 23.5 20.2 • Net Debt reduction of $4.7M. Inventories 31.9 27.9 Other current assets 3.6 2.3 Non-current assets 159.
Slide 8: Cashflow Summary
Cashflow Summary June 2023 June 2024 • Movement in net working capital due to decrease in inventories $4.0M, ($M) ($’M) decrease in receivables $3.1M and decrease in other assets $1.3M. Normalised EBITDA1 19.5 12.3 Income tax payments • Non-cash items relates to cost of Trajan’s long term employee s
Slide 9: Environment Social Governance
Environment Social Governance Trajan is in the early stages of building an ESG program from a strong foundation of being a purpose-led business. We are balancing our commitment to ESG with maintaining focus on our commercial success. Current Areas of ESG Focus 1. Establishing our Scope 1,2 and 3 em
Slide 10: Financial Guidance and Outlook
Financial Guidance and Outlook Net Revenue Group nEBITDA $160.0M-$165.0M $17.0M-$19.0M • Components & Consumables expected to continue at historical growth rates following the completion of destocking activity in FY24. • Capital Equipment H1 softer demand is expected within the pharmaceutical sector
Slide 11: Fundamentals Drive Growth Despite an Unprecedented FY24
Fundamentals Drive Growth Despite an Unprecedented FY24 • Return to growth is supported by a strong track record over 13 years. • Easing of supply chain volatility due to destocking provides greater certainty of short-to-medium-term performance. • Large defensive end-markets with structural growth d
Slide 12: Disclaimer
Disclaimer The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 29th August 2024. The information in the presentation is provided for information purposes only, is in summary form and does not
Slide 13: www.trajanscimed.com
= TRAJAN | Science that benefits people www.trajanscimed.com